DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson ’s disease
In conclusion, these studies support further evaluation of the repurposing of clinically approved gliptins as a treatment strategy for PD.
Source: AGE - Category: Geriatrics Source Type: research
More News: Brain | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Geriatrics | Incretin Therapy | Januvia | Methamphetamine | Neurology | Parkinson's Disease | Study